Boehringer, Zealand reframe diabetes pact
Boehringer Ingeleim and Zealand Pharma are still diabetes partners but have redefined the relationship they began in 2011.
The companies said in a joint statement that they will continue to collaborate on novel glucagon/GLP-1 dual agonists for diabetes or obesity, but ZP2929 is no longer the keystone compound.
Instead, Zealand gets all rights to ZP2929, and another agent will be swapped in. The companies said the original financial collaboration arrangements are staying put.